메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Nongshim Shin Ramyun Light Ups New York Times Square with 'KPop Demon Hunters'

[ 메디채널 김장윤(JASON KIM) 기자 ] - Global campaign celebrates the U.S. debut of the movie-inspired collaboration package - NEW YORK, Oct. 20, 2025 -- Nongshim carried out a global campaign at New York Times Square to celebrate the launch of Shin Ramyun in collaboration with Netflix's hit animated film 'KPop Demon Hunters'. As known for "The Crossroads of the World" and attracting over 450,000 visitors daily, Times Square served as the stage for global consumers to directly taste and enjoy the Shin Ramyun brand through a variety of interactive activities that seamlessly connected
- 김장윤(JASON KIM) 기자
- 2025-10-20 11:23
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Z
- 김갑성 기자
- 2025-10-20 10:36
Grand Opening of the 2025 Sustainable Global Leaders Conference: Kevin Kelly and the Turing Award Winner Share AI Frontiers, Business Leaders Discuss Sustainable Development

SHANGHAI, Oct. 20, 2025 -- Approved by the State Council, the 2025 Sustainable Global Leaders Conference opened on October 16 in Huangpu District, Shanghai. Centered around the theme "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth," the Conference brings together global wisdom and strength to explore new pathways for sustainable development, injecting powerful "Chinese dynamism" into global sustainable governance. The Conference is jointly organized by the World Green Design Organization (WGDO) and Sina Group, co-organ
- 황정호 기자
- 2025-10-20 10:20
Xinhua Silk Road: Financial Street Forum annual conference to be held on Oct. 27-30 in Beijing

BEIJING, Oct. 20, 2025 -- The annual conference of Financial Street Forum 2025 will be held on October 27-30 in Beijing. Over 400 delegates from more than 30 countries and regions will join the four-day conference, introduced by an official of the organizing committee of the forum at a press briefing here on Friday. This year's conference will include a main forum and several parallel forums, discussing topics on international and domestic economic situation and financial supervision, international financial governance and cooperation, high-quality financial opening up and how t
- 황정호 기자
- 2025-10-20 09:35
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

SHANGHAI and HONG KONG, Oct. 20, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.&nbs
- 김갑성 기자
- 2025-10-20 09:00
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled "Adjuvant Therap
- 김갑성 기자
- 2025-10-20 08:15
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration. - Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depo
- 김갑성 기자
- 2025-10-20 08:10
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

SUZHOU, China, Oct. 20, 2025 -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Key Highlights of CS2009 Poster Presentation:
- 김갑성 기자
- 2025-10-20 08:10
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group

SYDNEY, Oct. 20, 2025 -- The Brattle Group has welcomed Dr. Luke Wainscoat to its growing Sydney office as a Principal in the firm's Antitrust & Competition practice. An economist with 20 years of experience, Dr. Wainscoat advises clients on complex competition, regulatory, and damages matters in Australia and New Zealand. Recognized as one of Australia's top competition economists by Lexology Index (previously Who's Who Legal), Dr. Wainscoat's expertise includes merger clearance processes, cartel investigations, anticompetitive agreements, and misuses of market power. He h
- 황정호 기자
- 2025-10-20 07:25
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

SHANGHAI, Oct. 20, 2025 -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances. Dr. Jackson will work closely with the Company's CEO, Joshua Liang, to accelerate the development of Clover's RSV+hMPV±PIV3 combination vaccine candidates and lead potential alliances with global collaborators. "We are excited to welcom
- 김갑성 기자
- 2025-10-20 07:00

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-10-29_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 29일 10시 40분